ASH 2021 | 10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler
• 12 Dec 2021
Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from a follow up from an open-label Phase II trial (NCT00695786) of rituximab and lenalidomide (R2) in patients with low tumor burden follicular lymphoma (FL). After 10 years follow-up, a majority of patients treated with R2 remained in remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
